Effectiveness and Impact of Nirsevimab on medium to long-term RSV associated outcomes in Finland – Population-based registry study (RSV506)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  NIRSEVIMAB
• Medical condition to be studied:
  Asthma

Population studied

• Short description of the study population:
  All children born and residing in Finland who were eligible for nirsevimab immunoprophylaxis during the 2024–2025 RSV season. The primary study cohort includes infants born between 1 August 2024 and 30 March 2025.
• Age groups:
  • Neonate
  • Infants and toddlers (28 days – 23 months)
  • Children (2 to < 12 years)

Study design details

No information provided.